Markers of bone metabolism in eugonadal female patients with β-thalassemia major

Pediatric Hematology and Oncology

Volumn 24, Issue 7, 2007, Pages 481-491

  Angelopoulos, Nicholas G ^a   Goula, Anastasia ^b   Katounda, Eugenia ^a   Rombopoulos, Grigorios ^a   Kaltzidou, Victoria ^a   Kaltsas, Dimitrios ^a   Konstandelou, Evangellia ^c   Tolis, George ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b Ag Sophia Children's Hospital   (Greece)

^c General Hospital of Piraeus   (Greece)

Author keywords

thalassemia; Bone turnover; OPG sRANKL system; Osteoporosis

Indexed keywords

DEFEROXAMINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PREVALENCE; THALASSEMIA MAJOR;

ADULT; AMINO ACIDS; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; FEMALE; HUMANS; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 34548415050     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701533611     Document Type: Article

References (27)

1. Jensen CE, Tuck SM, Agnew JE, et al. High incidence of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab. 1998;11:975-977.
2. Anapliotou ML, Kastanias IT, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol. 1995;42:279-287.
3. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int. 2001;12:570-575.
4. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int. 2004;74:68-71.
5. De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr. 1996;155:368-372.
6. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassemia. Br J Haematol. 2004;127:127-139.
7. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14:518-527.
8. Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab. 2000;85:2355-2363.
9. Menaa C, Reddy SV, Kurihara N, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest. 2000;105:1833-1838.
10. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
11. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol. 2003;123:730-737.
12. Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19:722-727.
13. Saiku M, Inoue D, Kido S, Matsumoto T. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology. 2001;142:2205-2212.
14. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367-4370.
15. Liao EY, Luo XH, Su X. Comparison of the effects of 17β- E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Inv. 2002;25:785-790.
16. Lindsay R, Tohme JF, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and postmenopausal women. Contraception. 1986;34:333-340.
17. Prior JC, Kirkland SA, Joseph L, et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. Can Med Assoc J. 2001;165:1023-1029.
18. Hofbauer LC, Schoppet M, Schuller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol. 2004;60:214-219.
19. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
20. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001;86:3162-3165.
21. Riggs BL, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Khosla S. Evidence that postmenopausal women with vertebral fractures due to type I osteoporosis have enhanced responsiveness of bone to estrogen deficiency. J Bone Miner Res. 2001;16(Suppl 1):S281.
22. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13:1124-1133.
23. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002;87:4470-4475.
24. Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassemia major. Br J Haematol. 2001;112:36-41.
25. Alvarez L, Peris P, Guanabens N, et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 2003;48:824-828.
26. Buzi F, Maccarinelli G, Guaragni B, et al. Serum osteoprotegerin and receptor activator of nuclear factors κB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol. 2004;60:87-91.
27. Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology. 2003;42:123-134.